Moderna (Germany) Top Insiders

0QF Stock  EUR 34.91  1.14  3.38%   
Moderna employs about 3.9 K people. The company is managed by 23 executives with a total tenure of roughly 149 years, averaging almost 6.0 years of service per executive, having 169.57 employees per reported executive. Examination of Moderna's management performance can provide insight into the company performance.
Stephane Bancel  CEO
Chief Executive Officer, Director
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more detail on how to invest in Moderna Stock please use our How to Invest in Moderna guide.

Moderna Management Team Effectiveness

The company has return on total asset (ROA) of 0.233 % which means that it generated a profit of $0.233 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.5027 %, meaning that it generated $0.5027 on every $100 dollars invested by stockholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities.
Moderna maintains a total of 385 Million outstanding shares. Over half of Moderna's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Moderna. Please watch out for any change in the institutional holdings of Moderna as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Moderna in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Moderna, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Moderna Workforce Comparison

Moderna is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 6,205. Moderna totals roughly 3,900 in number of employees claiming about 63% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.43 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.49 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.49.

Moderna Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Moderna Price Series Summation is a cross summation of Moderna price series and its benchmark/peer.

Moderna Notable Stakeholders

A Moderna stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Moderna often face trade-offs trying to please all of them. Moderna's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Moderna's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Stephane BancelChief Executive Officer, DirectorProfile
David MelineChief Financial OfficerProfile
Francois NaderNon-Executive Independent DirectorProfile
Marcello DamianiChief Digital and Operational Excellence OfficerProfile
Shannon KlingerChief SecProfile
James MockChief OfficerProfile
Lori HendersonGeneral Counsel, Company SecretaryProfile
Tal ZaksChief Medical OfficerProfile
John ReyndersChief OfficerProfile
Paul SaganNon-Executive Independent DirectorProfile
Lavina CFAVP RelationsProfile
Melissa MooreChief BoardProfile
Elizabeth TallettDirectorProfile
Stephen HogePresidentProfile
Noubar AfeyanNon-Executive Independent Chairman of the Board, Co-FounderProfile
Stephen BerensonNon-Executive Independent DirectorProfile
Stephen MDPresidentProfile
Robert LangerNon-Executive Independent DirectorProfile
Tracey FranklinChief Human Resource OfficerProfile
Ray JordanChief Corporate Affairs OfficerProfile
Jerh CollinsChief OfficerProfile
Juan AndresChief Technical Operations and Quality OfficerProfile
Israel RuizNon-Executive Independent DirectorProfile
String symbol = request.getParameter("s");

About Moderna Management Performance

The success or failure of an entity such as Moderna often depends on how effective the management is. Moderna management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moderna management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moderna management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. MODERNA INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1800 people.

Moderna Workforce Analysis

Traditionally, organizations such as Moderna use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Moderna within its industry.

Moderna Manpower Efficiency

Return on Moderna Manpower

Revenue Per Employee4.9M
Revenue Per Executive837.5M
Net Income Per Employee2.1M
Net Income Per Executive363.6M

Complementary Tools for Moderna Stock analysis

When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume